Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-dose remifentanil infusion comparison during rhinoplasty
IRCT20200825048515N65Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of remifentanil (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Systolic blood pressure, Diastolic blood pressure and 7 more. Started Mar 2023; status: completed.
02
Drugs
remifentanil
Beyond the preview
Go deeper on IRCT20200825048515N65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N65.